Alnylam Pharmaceuticals Bolsa (NASDAQ: ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Bolsa

ALNYLAM PHARMACEUTICALS INC

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $364 to $404.

News

Price Target

Analyst Ratings

ALNY

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $404

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $336 to $359.

B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $359

Jefferies analyst Maury Raycroft maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $328 to $384.

Jefferies Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease
MISSISSAUGA, ON, July 2, 2025 /CNW/ -&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4458268-1&amp;h=820107370&amp;u=http%3A%2F%2Fwww.alnylam.com%2F&amp;a=Alnylam+Canada+ULC">Alnylam Canada ULC</a> is pleased to announce that OXLUMO&#xAE; (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients.
OXLUMO is the first therapy for PH1 approved in Canada, and among the first medications to be included on the common list of new drugs for rare diseases, as part of the Government of Canada's National Strategy for Drugs for Rare Diseases. The common list was developed to help patients with rare diseases have access to treatments as early as possible.

Alnylam Canada Says OXLUMO Is Now Funded Across Canada Through Both Public And Private Plans For Treatment Of PH1 In Pediatric And Adult Patients

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure. If that structure holds, the peak is likely to form in Phase 11, the classic culmination point of the Adhishthana Himalayan formation.
<h3 class="wp-block-heading">The Gap-Up Move &amp; Current Phase: Technical and Structural Alignment</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="814" height="522" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101105/ALNY-Stock-Weekly-Chart.png" alt="Fig.1 ALNY Stock Weekly Chart (Source: Adhishthana.com Reports)" class="wp-image-15137" style="width:524px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101105/ALNY-Stock-Weekly-Chart.png 814w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101105/ALNY-Stock-Weekly-Chart-300x192.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101105/ALNY-Stock-Weekly-Chart-768x493.png 768w" sizes="(max-width: 814px) 100vw, 814px" /><figcaption class="wp-element-caption">Fig.1 ALNY Stock Weekly Chart (Source: Adhishthana.com Reports)</figcaption></figure>
On June 24, ALNY gapped up by more than 30% after announcing that its drug Vutrisiran, used to treat transthyretin amyloid cardiomyopathy, delivered successful results. While the headline reason was fundamental, under the Adhishthana lens, this wasn't a random event.
The stock was in Phase 9 at the time, a phase known for triggering supreme moves and powerful shifts in structure. Phase 9 is also where the stock typically breaks out of its Adhishthana Cakra and begins forming the Himalayan structure. That's exactly what happened here. The gap-up and event aligned itself with the principles, both in sentiment and in form. Now in Phase 10, the stock is continuing its upward trajectory, holding firmly within a bullish stance.
<h3 class="wp-block-heading">Peak Formation Timing: Phase 10 Still in Play</h3>
According to the Adhishthana Principles, peak formation in Phase 10 generally occurs between the 18th and 23rd bars of the phase. ALNY, however, has yet to show any signs of a peak, suggesting the structure is still building. (Ref Fig 1)
As long as this setup remains intact, Phase 11 is likely to host the eventual peak followed by a correction.
<h3 class="wp-block-heading">Monthly Chart Insights: Cakra Formation and Nirvana Level</h3>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana--1024x594.png" alt="Fig.2 ALNY Stock Monthly Chakra Formation (Source: Adhishthana.com Reports)" class="wp-image-15141" style="width:529px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana--1024x594.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana--300x174.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana--768x446.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana-.png 1196w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Fig.2 ALNY Stock Monthly Chakra Formation (Source: Adhishthana.com Reports)</figcaption></figure>
On the monthly timeframe, ALNY is currently in Phase 6, a phase associated with the creation of the Nirvana level, which acts as both a value barometer and a magnet during future bearish periods.
The Nirvana level is yet to be finalized but will be structurally created on September 30, 2025. Current chart dynamics suggest the Nirvana zone is likely to emerge around $240, which will become a long-term reference point.
Also worth noting: starting from Phase 4, the stock has been forming its monthly Adhishthana Cakra, and is now trading near the upper arc of this structure. According to the framework, the underlying trades in this range with a breakout emerging in Phase 9. Considering this and the fact that Phase 10 is approaching maturity on the weekly chart, signs of exhaustion may emerge soon.
<h3 class="wp-block-heading">Investor Outlook: Hold with Caution, Avoid New Entries for Now</h3>
For existing investors, the strategy is to hold while closely monitoring the weekly chart for ALNY signs of a structural breakdown. A clear break would signal the beginning of the descent phase- the "Wrath of Ganga" in Adhishthana terminology, bringing the stock back toward its Nirvana level.
For potential entrants, Phase 10 is not an ideal entry zone, especially with the stock trading near the higher arc of the monthly Adhishthana Cakra. Chasing the momentum at this point would offer poor risk-reward dynamics.

Equities

Technicals

Opinion

Signals

Trading Ideas

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Alnylam Pharmaceuticals, revealing an average target of $352.22, a high estimate of $500.00, and a low estimate of $268.00. Surpassing the previous average price target of $330.22, the current average has increased by 6.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1751310017_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Alnylam Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$333.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$377.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$338.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Esther Rajavelu</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$349.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$284.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Alnylam Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Alnylam Pharmaceuticals Better</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>A Deep Dive into Alnylam Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Alnylam Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 20.2%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -9.67%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -62.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 11.28, Alnylam Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 9 Analysts

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 5 years by 2.17% on an annualized basis producing an average annual return of 16.39%. Currently, Alnylam Pharmaceuticals has a market capitalization of $41.78 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 5 years ago, it would be worth $2,172.18 today based on a price of $322.83 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751292948_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Tiago Fauth maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Equal-Weight and raises the price target from $287 to $333.

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $333

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan cut Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $240 to $230. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares closed at $201.56 on Wednesday. S<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from $167 to $145. Jefferies analyst Kaumil Gajrawala maintained a Buy rating. Clorox shares closed at $119.48 on Wednesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) price target from $69 to $81. Canaccord Genuity analyst Brian McNamara maintained a Buy rating. Worthington shares closed at $61.35 on Wednesday. <a href="https://www.benzinga.com/quote/WOR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co boosted the price target for Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) from $54 to $60. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Kymera Therapeutics shares closed at $46.47 on Wednesday. <a href="https://www.benzinga.com/quote/KYMR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from $74 to $68. Wells Fargo analyst Alec Brondolo downgraded the stock from Overweight to Equal-Weight. Trade Desk shares closed at $69.80 on Wednesday. <a href="https://www.benzinga.com/quote/TTD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup raised Truist Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) price target from $44 to $55. Citigroup analyst Keith Horowitz upgraded the stock from Neutral to Buy. Truist Financial shares settled at $41.40 on Wednesday. <a href="https://www.benzinga.com/quote/TFC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $172 to $200. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. Micron shares closed at $127.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $320 to $377. Needham analyst Joseph Stringer maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $321.94 on Wednesday.  <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $350 to $475. Benchmark analyst Mickey Legg maintained a Buy rating. Tesla shares settled at $327.55 on Wednesday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) price target from $62 to $72. Baird analyst David Koning maintained an Outperform rating. Concentrix shares closed at $54.17 on Wednesday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-1024x570.png" alt="" class="wp-image-963276" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Markets

AAPL

CNXC

KYMR

TSLA

Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday

Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $320 to $377.

Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $377

BMO Capital analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $300 to $360.

BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $360

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 12.09% on an annualized basis producing an average annual return of 20.51%. Currently, Alnylam Pharmaceuticals has a market capitalization of $39.93 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $40,864.67 today based on a price of $308.54 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750089617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years

Ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00. Surpassing the previous average price target of $324.29, the current average has increased by 4.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1749736915_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Alnylam Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$338.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Esther Rajavelu</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$349.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$284.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$342.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Joshua Smith</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$353.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$351.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$338.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$287.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Alnylam Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Alnylam Pharmaceuticals Better</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Alnylam Pharmaceuticals's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 20.2%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -9.67%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -62.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 11.28, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and raises the price target from $330 to $338.

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $338

The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis in adults.

Biotech

Health Care

General

The European Commission Approves  Alnylam Pharmaceuticals' Orphan RNAi Therapeutic Amvuttra (Vutrisiran) For Wild-type Or Hereditary Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy As An Additional Indication

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court&#8217;s finding of noninfringement in favor of Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) in its ongoing patent battle with Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over mRNA-based <a href="https://www.benzinga.com/topic/covid-19">COVID-19 vaccine technology</a>, including its Spikevax COVID-19 vaccine.
The court held that Alnylam had acted as its lexicographer in defining the term &#8220;branched alkyl&#8221; in its patent specifications. That definition was included in Alnylam&#8217;s infringement allegations against Moderna&#8217;s Spikevax vaccine.
The <a target="_blank" href="https://www.cafc.uscourts.gov/opinions-orders/23-2357.OPINION.6-4-2025_2525006.pdf" rel="noreferrer noopener">case</a> centered on whether Alnylam&#8217;s patents, U.S. Patent Nos.&nbsp;11,246,933&nbsp;and&nbsp;11,382,979 were infringed by Moderna&#8217;s use of SM-102-a cationic lipid in Moderna&#8217;s COVID-19 vaccine formulations.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
Alnylam asserted that SM-102 fell within the scope of its claims, specifically limitations requiring a &#8220;branched alkyl&#8221; group in the hydrophobic tail of a cationic lipid. SM-102 enables intracellular delivery of mRNA in Moderna&#8217;s vaccine, making it central to Alnylam&#8217;s infringement theory.
In March 2022, Alnylam sued Moderna, alleging that Moderna infringed claim 18 and other claims of the '933 patent through activities involving the SM-102 lipid in its mRNA-based COVID-19 vaccine.
In July 2022, after the '979 patent was issued, Alnylam filed a similar suit against Moderna in the same forum, alleging infringement of claim 1 and other claims of the '979 patent. The two <a target="_blank" href="https://www.benzinga.com/general/biotech/22/07/28082091/alnylam-hits-moderna-with-another-patent-infringement-suit-related-to-covid-19-vaccine" rel="noreferrer noopener">actions were consolidated</a>.
In October 2024, Alnylam and&nbsp;Moderna reached a stipulation in their ongoing&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41169029/alnylams-concedes-its-patent-infringement-case-against-modernas-covid-19-vaccine" rel="noreferrer noopener">patent infringement litigation</a>.
Based on the court&#8217;s claim construction, Alnylam acknowledged it couldn&#8217;t secure a favorable judgment regarding the accused products&#8217; infringement of its patents.
The final stipulation allows for judgment in favor of Moderna, confirming that its currently formulated products do not infringe on Alnylam&#8217;s patents.
Both parties have agreed to dismiss the counterclaims and affirmative defenses raised by Moderna without prejudice, leaving the door open for further legal action if necessary in the future.
In October 2024, Northwestern University filed a patent infringement lawsuit against&nbsp;Moderna, alleging the pharmaceutical company used the university&#8217;s lipid nanoparticle (LNP) technology without permission to develop&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology" rel="noreferrer noopener">its COVID-19 vaccines.</a>
According to the&nbsp;<a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/dwpkkdaxjpm/NORTHWESTERN%20MODERNA%20PATENT%20LAWSUIT%20complaint.pdf?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">lawsuit</a>, the development of Moderna&#8217;s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern.
Recently, The U.S. Food and Drug Administration (FDA) approved Moderna&#8217;s mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factors as defined by the Centers for Disease&nbsp;<a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
Moderna shared Phase 3 immunogenicity data for its flu/COVID combination vaccine (mRNA-1083) for adults aged 50 and older at its 2024 R&amp;D Day event.&nbsp;
The company submitted mRNA-1083 for regulatory approval in older adults in 2024. Based on FDA feedback confirming the need for Phase 3 flu efficacy data, Moderna expects an extended review timeline and is now <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45145598/moderna-expands-cost-cutting-program-by-up-to-17-billion-fda-approval-for-flucovid-19-combo-shot-delayed-into-2026" rel="noreferrer noopener">targeting approval in 2026</a>.
Price Action: MRNA stock is down 1.32% at $26.91, and ALNY stock is up 0.69% at $307.43 at last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45790736/ciena-stock-slides-after-q2-eps-miss-margin-drop-despite-strong-sales" target="_blank" rel="noreferrer noopener">Ciena Stock Slides After Q2 EPS Miss, Margin Drop Despite Strong Sales</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Large Cap

Legal

MRNA

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 12.14% on an annualized basis producing an average annual return of 20.3%. Currently, Alnylam Pharmaceuticals has a market capitalization of $36.66 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on a price of $283.25 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748302212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today

– Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin –
– Additional 42-Month Data Reinforce Vutrisiran's Impact on the Risk of All-Cause Mortality and Further Underscore the Effect on Cardiovascular Mortality –
– Vutrisiran Demonstrated Substantial Benefit Across a Range of Cardiovascular Events, Notably Reducing Urgent Heart Failure Visits by 46% in the Overall Patient Population During the Double-Blind Period –
– Findings Simultaneously Published in JACC –
– Details of TRITON-CM Phase 3 Study Evaluating Alnylam's Investigational Next-Generation TTR Silencer, Nucresiran, to be Presented at Congress –

Reported Saturday, Alnylam's Vutrisiran Reduces All-Cause And Cardiovascular Mortality By Over 30% In ATTR-CM Patients, New 42-Month HELIOS-B Data Show

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54252800&amp;newsitemid=20250512731729&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=c09d64a6df2c8aec7de70fcaf5351a15">Alnylam Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia.
The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract in the "Hottest Trials and Trial Updates 1" session.
Data from the HELIOS-B study supported the recent approvals of AMVUTTRA&#xAE; (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of vutrisiran for the same indication. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year.
Additional updates to be presented include the design and rationale of the TRITON-CM Phase 3 study of nucresiran (ALN-TTRsc04), an investigational next-generation TTR silencer, in patients with ATTR-CM, as well as an additional analysis from the HELIOS-B study of vutrisiran in patients with ATTR-CM who experienced disease progression while being treated with tafamidis.

Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.44 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,535.06 today based on a price of $258.35 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746743413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Press Releases

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

Comments

Alnylam Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL